Journal for ImmunoTherapy of Cancer | Clinical Trials Monitor

Journal for ImmunoTherapy of Cancer | Clinical Trials Monitor



Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)

Clinical Trials Monitor

Section edited by Leisha A. Emens, MD, PhD

Reports on important new trial results; updates on new drug approvals and ongoing clinical studies; key perspectives on clinical issues and advances in the field relevant to the everyday use of cancer immunotherapy in the clinic. This section also aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic.

1. CLINICAL TRIALS MONITOR

   Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

   With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place ...

   Hasan Rehman, Ann W. Silk, Michael P. Kane and Howard L. Kaufman

   Journal for ImmunoTherapy of Cancer 2016 4:53

   Published on: 20 September 2016

   • Full Text
   • PDF
2. CLINICAL TRIALS MONITOR

   Current clinical trials testing the combination of immunotherapy with radiotherapy

   Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion...

   Josephine Kang, Sandra Demaria and Silvia Formenti

   Journal for ImmunoTherapy of Cancer 2016 4:51

   Published on: 20 September 2016

   • Full Text
   • PDF
3. CLINICAL TRIALS MONITOR

   PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

   Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between check...

   Claud Grigg and Naiyer A. Rizvi

   Journal for ImmunoTherapy of Cancer 2016 4:48

   Published on: 16 August 2016

   • Full Text
   • PDF
4. CLINICAL TRIALS MONITOR

   Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

   Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi...

   David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

   Journal for ImmunoTherapy of Cancer 2016 4:25

   Published on: 17 May 2016

   • Full Text
   • PDF
5. EDITORIAL

   Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer

   Leisha A. Emens and Pedro Romero

   Journal for ImmunoTherapy of Cancer 2015 3:49

   Published on: 20 October 2015

   • Full Text
   • PDF